PathoVacs
Speeding vaccine development. PathoVacs lowers cost, speeds up identification of protein antigens with potential for universal protection
- Stage Product In Development
- Industry Biotechnology
- Location Ames, IA, USA
- Currency USD
- Founded September 2009
- Employees 1
- Website pathovacs.com
Company Summary
PathoVacs uses a very clever and innovative technology for rapid discovery of protein antigens for universal vaccines against infectious agents that cause disease both in humans and livestock. Potenial customers include established biologics companies for antigen discovery services, and sub-licensees, and major vaccines companies for partnered development of proprietary vaccines developed to the experimental vaccine stage "in house."
Team
-
Chuck SoponisCEO
Chuck Soponis, has led nine startup companies, achieving two IPO and three acquisition exits.
-
Manohar JohnChief Scientific Officer
Dr. Manohar John, is the Founder of Pathovacs, and the inventor of the PELS antigen discovery technology. Dr. John is extensively experienced in
preclinical bacterial vaccine development acquired both as faculty at Massachusetts General Hospital and Harvard Medical School, and as Director of Biomarker Discovery in industry.
Advisors
-
NyemasterLawyerUnconfirmedLWBAccountantUnconfirmed
Previous Investors
-
Manohar John, FounderUnconfirmedIowa Department of Economic DevelopmentUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.